Results 101 to 110 of about 170,488 (349)
BMC Cancer, 2019 Background Chronic lymphocytic leukemia is a malignancy with good prognosis. However, the incidence of secondary tumors increases every year after the diagnosis of chronic lymphotcytic leukemia. One of the induced secondary tumors is prostate cancer. For
Yinjie Zhu +6 more
doaj +1 more source
Advanced Science, EarlyView.This study demonstrates that BNNT exposure disrupts lipid homeostasis in bronchial epithelial cell cultures and activates eicosanoid lipid biosynthesis, producing inflammatory lipid mediators like leukotrienes. These effects are more pronounced in asthmatic cell cultures compared to healthy ones.
Govind Gupta +14 more
wiley +1 more source
Haematologica, 2018 Despite the recent discovery of recurrent driver mutations in chronic lymphocytic leukemia, the genetic factors involved in disease onset remain largely unknown.
Andreas Agathangelidis +10 more
doaj +1 more source
Preleukemia: hematological disorders prior to onset of leukemia [PDF]
, 1975 Published data on Japanese leukemia patients with a preleukemic hematological disorder were assessed. The reexamined cases were from the "Japona Centra Revuo Medicina" reported during the period from 1952 to 1971.
Hiraki, Kiyoshi +5 more
core +1 more source
Alemtuzumab in Chronic Lymphocytic Leukemia
Current Oncology, 2007 Questions: (1) With respect to outcomes such as survival, response rate, response duration, time to progression, and quality of life, is alemtuzumab a beneficial treatment option for patients with B-cell chronic lymphocytic leukemia (CLL)? (2) What toxicities are associated with the use of alemtuzumab? (3) Which patients are more likely—or less likely—
Fraser, G. +3 more
openaire +2 more sources
GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy
Advanced Science, EarlyView.Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu +11 more
wiley +1 more source
Haematologica, 2010 Background Bortezomib has been successfully used in the treatment of multiple myeloma and has been proposed as a potential treatment for chronic lymphocytic leukemia.
Maria Baou +9 more
doaj +1 more source
Lack of extensive mutations in the VH5 genes used in common B cell chronic lymphocytic leukemia. [PDF]
, 1993 B cell chronic lymphocytic leukemia (CLL) is a malignancy of the CD5+ B cells. Prior studies indicated that CLL B cells generally express immunoglobulin (Ig) VH and VL genes with little or no somatic mutations.
Kipps, TJ, Rassenti, LZ
core
Biomarkers of leukemia risk: benzene as a model. [PDF]
, 1998 Although relatively rare, leukemias place a considerable financial burden on society and cause psychologic trauma to many families. Leukemia is the most common cancer in children.
Smith, MT, Zhang, L
core +3 more sources
Advanced Science, EarlyView.Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang +7 more
wiley +1 more source